Carlsmed (CARL) Stock Price, News & Analysis

Company Overview

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning. The platform is designed to help surgeons plan alignment and select an implant configuration based on patient-specific imaging and clinical requirements.

Carlsmed is headquartered in Carlsbad, California, and serves the spine-care market through relationships with hospitals, surgeons and other healthcare providers. The company’s products are primarily focused on the United States market, where its technology is subject to regulatory clearance and use in accordance with applicable medical-device requirements.

Key Stats

• Today's Range: $13.41 to $14.30
• 50-Day Range: $13.41 to $16.88
• 52-Week Range: $8.50 to $17.23
• Volume: 73,221 shs
• Average Volume: 80,104 shs
• Market Capitalization: $366.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.50
• Consensus Rating: Moderate Buy

Carlsmed Stock Analysis - MarketRank™

Carlsmed scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Carlsmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Carlsmed has a consensus price target of $19.50, representing about 45.4% upside from its current price of $13.41.

Amount of Analyst Coverage

Carlsmed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Carlsmed are expected to decrease in the coming year, from ($1.50) to ($1.53) per share.

Price to Book Value per Share Ratio

Carlsmed has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.43% of the float of Carlsmed has been sold short.

Short Interest Ratio / Days to Cover

Carlsmed has a short interest ratio ("days to cover") of 14.28, which indicates bearish sentiment.

Change versus previous month

Short interest in Carlsmed has recently decreased by 2.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carlsmed does not currently pay a dividend.

Dividend Growth

Carlsmed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Carlsmed has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Carlsmed this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for CARL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Carlsmed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Carlsmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,149.00 in company stock.

Percentage Held by Insiders

12.90% of the stock of Carlsmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Carlsmed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CARL
• CIK: 1794546
• Web: carlsmed.com
• Phone: (858) 295-9290
• Fax: N/A
• Employees: 127
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Carlsmed: $19.50
• High Price Target: $24.00
• Low Price Target: $17.00
• Potential Upside/Downside: +45.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.63 million
• Net Margins: -57.42%
• Pretax Margin: -57.42%
• Return on Equity: -38.06%
• Return on Assets: -28.96%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 8.84
• Quick Ratio: 8.66

Sales & Book Value

• Annual Sales: $50.51 million
• Price / Sales: 7.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.72 per share
• Price / Book: 3.60

Miscellaneous

• Outstanding Shares: 27,300,000
• Free Float: 23,781,000
• Market Cap: $366.09 million
• Optionable: N/A
• Beta: 2.09